PATENT CLAIM ANALYSIS

Application Number: 16230090
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "246000"]

Abstract:
Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.

Claim (Index 1):
A pharmaceutical composition comprising a crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol mesylate and at least one pharmaceutically acceptable carrier or adjuvant, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially similar to  FIG. 40 .

Metadata:
- Claim Count in Document: 26.0
- Percentile: 98.0
- Lexical Diversity: 1.13043
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15548737', '15649551', '14909451', '14868283', '15612984']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7926309924750462
- 35 USC 102 Novelty (BERT): 0.6140675169386042
- Combined Prediction Score: 0.774774644921402
- Mean Citation Score: 456.9320960000002
- Max Citation Score: 561.4229
- Similarity Product: 508.0968774125935

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test